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The co-existence of hepatitis B surface antigen (HBsAg) and anti-HBs antibodies (HBsAb) in serum of hepatitis B virus (HBV)-chronic
carriers has been previously associated with HBsAg-amino acid (aa) substitutions. However, the aa pattern of HBV-reverse transcriptase (RT) and
the clinical settings associated with this serological profile remain largely unknown. We studied thirteen HBsAg-positive/HBsAb-positive patients.
Newly diagnosed HBsAg-positive/HBsAb-negative patients (n=51) served as controls. HBsAg/RT sequences were obtained using in-house
protocols. HBsAg-positive/HBsAb-positive patients were predominantly immunosuppressed (69%). Five presented advanced liver fibrosis. HBV
DNA N5.0 log10 copies/ml was significantly more frequent than in controls. A significantly higher aa variability was observed versus controls
within HBsAg major hydrophilic region (MHR), especially the a-determinant, and within RT for regions overlapping the MHR, the a-determinant,
and HBsAg C terminal region where drug resistance mutations occur. Further studies are needed to determine whether this higher HBsAg/HBV-
RT variability might favor dissemination of anti-HBsAb escape HBV mutants and concomitantly alter nucleos(t)ide analogs efficacy.
© 2007 Elsevier Inc. All rights reserved.Keywords: Hepatitis B virus; Concurrent HBsAg and anti-HBs antibodies detection; HBV mutants; HBV reverse transcriptase; HBV chronic infectionIntroduction
Hepatitis B virus (HBV) infection is a global public health
problem. About 350 million people worldwide are chronic
carriers of HBV and have a 15% to 25% risk of dying from
HBV-related liver disease (Poland and Jacobson, 2004; WHO,
2002). HBV clearance is classically characterized by the
occurrence of anti-HBs antibodies (anti-HBsAb) homologous
to the hepatitis B surface antigen (HBsAg), which contains
several important antigenic epitopes, in particular the “a”⁎ Corresponding author. Laboratoire de Virologie, Fédération Hospitalière de
Bactériologie-Virologie Clinique et d'Hygiène, Centre Hospitalier Universitaire
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doi:10.1016/j.virol.2007.05.012determinant that spans amino acids 124–147 within its major
hydrophilic region (MHR) (Carman, 1997; Torresi et al., 2002b;
Weber, 2005). Hence, in routine clinical practice, HBsAg and
anti-HBsAb are classically not detected concomitantly in sera of
individuals with present HBV infection.
However, chronic HBV infection and replication is able to
occur despite the presence of commonly considered “protec-
tive” anti-HBsAb in the serum of infected individuals. In these
patients, concurrent detection of HBsAg and anti-HBsAb might
be related to the emergence of HBsAg HBV mutants (Lada et
al., 2006; Margeridon et al., 2005; Weinberger et al., 1999).
Indeed, it has been reported that mutations in and around the “a”
determinant may result in alteration of the antigenicity of the
HBs protein and potential subsequent failure of neutralization
by anti-HBsAb (Carman, 1997; Carman et al., 1990; Weber,
2005; Weinberger et al., 2000; Zheng et al., 2004).
31P. Colson et al. / Virology 367 (2007) 30–40Such HBsAg mutants have been described following active
or passive immunization especially in hepatic graft recipients
and newborns from HBsAg-positive mothers (Carman et al.,
1990; Hsu et al., 1999; Protzer-Knolle et al., 1998). Several
HBsAg mutations have been observed in immune escape HBV
mutants, the G-to-R substitution at position 145 of HBsAg
being the most widely described (Carman, 1997; Weber, 2005;
Zheng et al., 2004).
The co-existence of HBsAg and anti-HBsAb might be
associated with important clinical concerns. Indeed, such
HBsAg-mutated HBV strains may not be fully sensitive to
vaccine-induced anti-HBsAb with the potential risk of vaccine
failure including contamination of presumably protected
vaccinated individuals. The detection of such non-protective
anti-HBsAb may also lead to misdiagnose chronic HBV
infection if detection of HBsAg is not carried out concomitantly.
Furthermore, due to the frame-shifted overlap between the open
reading frames of HBsAg and HBV polymerase genes,
mutations within HBsAg gene might result in structural and
functional alterations in the HBV reverse transcriptase (RT)
with potential influence on viral replication capacity and
efficacy of antiviral drugs (Sheldon et al., 2006; Torresi et al.,
2002a, 2002b). In view of these potential implications, the
frequency, clinical and virological settings and significance of
the presence of concurrent HBsAg and anti-HBsAb in serum
remain largely unknown to date.
Therefore, we aimed (i) to determine the prevalence of the co-
existence of HBsAg and anti-HBsAb in HBsAg carriers
diagnosed inMarseilles public hospital over an 18-month period
and (ii) to analyze the clinical and virological features, including
HBV HBsAg and RT amino acid substitutions, associated with
this serological pattern.
Results
Characteristics of HBsAg+/anti-HBsAb+ patients
Among the 24,089 patients tested for their HBV serological
status, 459 (1.9%) were HBsAg-positive. Thirteen (2.8%) of
these patients were concomitantly anti-HBsAb positive. The
HBsAg+/anti-HBsAb+ patients had a median age of 59 years
(range, 25–86), eight (62%) were male (Table 1). Immuno-
suppression concerned nine (69%) patients (kidney transplan-
tation, n=4; HIV-1 infection, n=2; prolonged corticotherapy,
immunosuppressive chemotherapy or myelodysplasia, one
patient each). Alanine aminotransferase levels were elevated
in five (42%) of twelve individuals and prothrombin time was
≤80% in three patients. METAVIR score was obtained in
8 patients, and advanced fibrosis (F3 or F4) was noted in
3 (38%).
Only one patient (Mar-7) was under anti-HBV therapy at time
of first detection of HBsAg/anti-HBsAb co-existence (Table 1).
Hewas treated with lamivudine (LAM) plus tenofovir disoproxil
fumarate (TDF) and was infected with HBV harbouring LAM
resistance mutations rtL180M and rtM204V. This patient was
the only one whose HBV did not harbour amino acid (aa)
substitution within the “a” determinant of HBsAg. No otherHBsAg+/anti-HBsAb+ patient underwent anti-HBV therapy
before initial HBV DNA sequencing, whereas four individuals
subsequently received anti-HBV therapy (LAM, n=3; LAM
plus adefovir dipivoxil (ADV), n=1).
Virological characteristics of HBV infection in
HBsAg+/anti-HBsAb+ patients
HBsAg and anti-HBsAb both persisted more than 2 months
in six (86%) of seven patients with available sequential samples.
Mean and median titers of anti-HBsAb were 41 and 22 mIU/ml,
respectively (range, 11–155). In seven of ten individuals, anti-
HBsAb positivity was confirmed using our alternative assay
(Vidas BioMérieux) (Table 1). In contrast, in the three remaining
patients, anti-HBsAb titers were found b10 mIU/ml using the
alternative diagnosis assay. In addition, in one patient (Mar-11),
HBsAg was not detected using the alternative diagnosis assay.
HBsAg sequences were obtained from eleven (85%) of 13
HBsAg+/anti-HBsAb+ patients, which is significantly more
frequent than in the control group (41%; p=0.003) (Table 2).
Moreover, the proportion of patients with HBV DNA N5.0
log10 copies/ml was significantly higher in HBsAg+/anti-
HBsAb+ patients than in controls (54% vs. 17%; p=0.003)
(Table 2). HBV genotypes D and A were preponderant in
HBsAg+/anti-HBsAb+ individuals and controls, respectively
(Table 2).
HBsAg sequences
HBsAg sequences obtained from eleven HBsAg+/anti-
HBsAb+ patients were compared with those from 51 newly
diagnosed HBV chronic carriers without anti-HBsAb (control
group; Tables 3 and 4; Fig. 1).
A significantly higher aa variability was observed within the
MHR of HBV from HBsAg+/anti-HBsAb+ individuals than
from controls (mean number of substitutions per 100 aa of 4.68
vs. 2.07, respectively; p=0.030) (Table 3). This involved
mainly the “a” determinant (mean number of substitutions per
100 aa of 11.00 vs. 2.48, respectively; p=0.013). Both
subregions 3 and 4 of the “a” determinant were more variable
in HBsAg+/anti-HBsAb+ patients than in controls (3.4- and
8.4-fold higher variability per 100 aa within subregions 3 and 4,
respectively). Although these differences only tended to be
statistically significant (p=0.086 and 0.090, respectively), the
proportion of sequences harbouring N2 aa substitutions was
significantly higher from HBsAg+/anti-HBsAb+ patients than
from controls in HBsAg subregions 3 (45% vs. 12%, p=0.009)
and 4 (18% vs. 0%, p=0.0002). In these two areas, around 50%
of aa positions were found variable, with numbers of mutations
per sequence ranging from 0 to 4 in subdomain 3 (mean, 1.2±
0.44) and from 0 to 3 in subdomain 4 (mean, 1.3±0.61).
As regards to specific aa substitutions, they were signifi-
cantly more frequent at eleven positions in sequences from
HBsAg+/anti-HBsAb+ patients than from controls (pb0.05;
Table 4, Fig. 1). Seven of these positions stand within the MHR
(six within its “a” determinant), 3 in the N terminal region and 1
in the C terminal region.
Table 1
Epidemiological, clinical, virological, biological and histological features for patients with concurrent HBsAg and anti-HBs in serum
Patient no. Gender/age HBsAg Anti-HBs
(mIU/ml)
HBV DNA
(log10 cp/ml)
HBV
genotype
HBeAg/
anti-HBe
HIV/HCV
serological
status
Clinical context Immunosuppressive
therapy
ALT
level
Prothrombin
time (%)
Histology a HBV treatment
Axsym
assay b
Vidas
assay c
Axsym
assay
Vidas
assay
Mar-1 M/86 21 5 14 44 Neg N.a. Neg/Pos Neg/Neg None No N 100 N.a. None
Mar-2 F/58 184 243 101 126 N9.0 D Pos/Neg Neg/Neg Kidney
transplantation
Yes (cyclosporine) N 100 A1F0 None then LAM
Mar-3 F/25 349 509 16 b5 6.4 E Neg/Pos Neg /Neg None No N 100 A2F1 None
Mar-4 M/47 222 515 17 b5 4.3 D Neg/Pos Neg/Neg Kidney
transplantation
Yes (cyclosporine) N 98 A0F0 None
Mar-5 M/37 113 10 24 b5 Neg N.a. Neg/Pos Neg/Pos Epilepsy No N 72 N.a. None
Mar-6 F/75 6 N.a. 11 N.a. 2.2 B Neg/Pos Neg/Neg Rheumatoid
polyarthritis
Yes (corticosteroids) 1.5xN 100 A1F0 d None
Mar-7 M/45 257 495 22 86 N8 A Neg/Neg Pos/Pos HIV infection No N 92 A3F3 LAM plus TDF
Mar-8 M/70 196 237 35 38 6.9 D Neg/Neg Pos/Neg HIV infection No 3xN 80 N.a. None then LAM
Mar-9 M/85 327 N.a. 11 N.a. 8.5 D Pos/Neg Neg/Neg Myelodysplasia No N 50 F4 None
Mar-10 F/66 181 10 30 32 3.3 D Neg/Pos N.a./Neg Hemochromatosis No 1.5xN 94 N.a. None
Mar-11 M/68 93 0.03
(Neg)
155 77 6.9 D Pos/Neg Neg/Neg Kidney transplantation Yes (cyclosporine) 2.5xN 100 A2F3 d None then
ADV+LAM
Mar-12 F/50 184 N.a. 79 N.a. 7.1 A/D Neg/Pos Neg/Neg Breast carcinoma/Acute
myeloid leukemia
Yes (chemotherapy) N.a. 95 N.a. None then LAM
Mar-13 M/51 5 16 1.5 81 2.6 D Neg/Pos Neg/Neg Kidney transplantation Yes (tacrolimus) 1.5xN 88 A1F0 None
M, male; F, female; Pos, positive; Neg, negative; N.a., not available; ALT, alanine amino transferase; LAM, lamivudine; ADV, adefovir dipivoxil; TDF, tenofovir disoproxil fumarate; HBsAg, HBs antigen; anti-HBsAb,
anti-HBs antibodies; HBeAg, HBe antigen; anti-HBe, anti-HBe antibodies; HIV, human immunodeficiency virus; HCV, hepatitis C virus.
a According to Metavir score.
b Signal/negative-value ratio, positivity threshold: ≥2.0.
c Index values, positivity threshold: ≥1.1.
d As assessed by the Fibrotest assay.
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Table 2
Comparative analysis of epidemiological and virological features of patients
with concurrent HBs antigen and anti-HBs antibodies in serum and controls
Patients with
concomitant HBsAg
and anti-HBsAb
(n=13)
Control group
(n=123)
Median age (years) 58 43
Gender (M/F) 8/5 79/44
Male (%) 62% 64%
HIV seropositivity (%) 2/12 (16.7%) 17/82 (20.7%)
HCV seropositivity (%) 2/13 (15.4%) 11/97 (11.3%)
Anti-HBe-positivity (%) 8/13 (62%) 102/122 (83.6%) p=0.052
HBV DNA detection
(HBsAg/RT genes PCR
and sequencing) (%)
11/13 (85%) 51/123 (41.4%) p=0.003
HBV DNA quantification
b3 log10 copies/ml 4/13 (29%) 50/94 (53%) p=0.13
N5 log10 copies/ml 7/13 (54%) 16/94 (17%) p=0.003
HBV genotype
(RT gene) (%)
n=11 n=51
A 1/11 (9.1%) 26/51 (51%)
B 1/11 (9.1%) 0/51 (0%)
C 0/11 (0%) 2/51 (1.2%)
D 7/11 (64%) 18/51 (35%) p=0.082
E 1/11 (9.1%) 5/51 (9.8%)
Mixed (A/D) 1/11 (9.1%) 0/51 (0%)
Non A 9/11 (82%) 25/51 (49%) p=0.047
HBsAg, HBs antigen; anti-HBsAb, anti-HBs antibodies; M, male; F, female;
anti-HBe, anti-HBe antibodies; RT, reverse transcriptase.
33P. Colson et al. / Virology 367 (2007) 30–40Mutation sG145R/Twithin the “a” determinant was the most
frequently encountered, being present in 36% of HBV
sequences from HBsAg+/anti-HBsAb+ patients compared to
2% of HBV sequences from controls. Mutation sW165S (MHR
subregion 5) was found in 27% of sequences in HBsAg+/anti-
HBsAb+ individuals.Table 3
Number of substitutions per 100 amino acid positions within HBsAg and overlapping
Regions of HBsAg a Number of substitutions per 100 amino acid positio
HBsAg
HBsAg+/anti-HBsAb+
patients
Controls
N-terminal region 1.93 1.94
MHR (aa 100–169) 4.68 2.07
“a” determinant 11.00 2.48
Region 1 2.16 2.71
Region 2 9.10 6.86
Region 3 10.60 3.10
Region 4 11.69 1.40
Region 5 2.60 1.31
C terminal region 4.11 3.82
Complete HBsAg 3.33 2.45
Complete RT – –
HBsAg, HBs antigen; anti-HBsAb, anti-HBs antibodies; aa, amino acid; MHR, maj
a For analysis, HBsAg was divided into subregions corresponding to structural an
hydrophilic region (MHR; amino acid 100 to 169) and the C terminal region (ami
(amino acid 100 to 120), HBsAg subregion 2 (amino acid 121 to 123), HBsAg subreg
HBsAg subregion 5 (amino acid 148 to 169) (Cooreman et al., 2001). The “a” detHBV reverse transcriptase sequences and antiviral resistance
Regions of RT overlapping the subregions of HBsAg were
separately analyzed to appreciate the potential impact of HBsAg
variability on RT variability.
When an aa substitution was found within HBsAg, the
corresponding aa position within RT was mutated in 38% of
cases. This frequency reached 42% and 52% within RT regions
overlapping the MHR and the “a” determinant, respectively.
Not surprisingly, the most variable regions within the RT were
those overlapping the HBsAg MHR and most particularly the
“a” determinant that stand within a structural and functional
“finger” subdomain of the enzyme (Table 3; Fig. 2) (Lin et al.,
2001). In those regions, the proportion of RT sequences
harbouring at least two aa substitutions was significantly higher
in HBsAg+/anti-HBsAb+ patients than in controls (73% vs.
29% in the HBsAgMHR (p=0.007) and 45% vs. 14% in the “a”
determinant (p=0.017), respectively).
We paid particular attention to the RT region that overlaps
the C terminal region of HBsAg and stands within the structural
and functional “palm” subdomain of the enzyme (Lin et al.,
2001). Indeed, it spans subdomains B, C and D of HBV RT,
within which mutations described as conferring resistance to
antiviral drugs occur. Importantly, in this RT region, the mean
number of substitution per 100 aa showed a tendency to be
significantly higher in HBsAg+/anti-HBsAb+ patients than in
controls (p=0.124; Table 3). In addition, the proportion of RT
sequences harbouring at least two aa substitutions was
significantly higher in HBsAg+/anti-HBsAb+ patients than in
controls (45% vs. 18%; p=0.047).
As regards to specific aa substitutions, mutations rtI16T,
rtD134E, rtS135T/Y/N, rtR138N/K and rtR/W153Q/K/H were
significantlymore frequent inHBV fromHBsAg+/anti-HBsAb+
patients than from controls (pb0.05; Table 4). It should be notedregions of reverse transcriptase for HBsAg+/anti-HBsAb+ patients and controls
ns
HBsAg overlapping regions of reverse transcriptase
p HBsAg+/anti-HBsAb+
patients
Controls p
1.45 1.06
0.030 3.64 2.89
0.013 7.66 3.51
3.90 5.42
9.10 3.90
0.086 7.58 2.29 0.145
0.090 7.79 5.60
0.00 0.28
2.47 1.34 0.124
0.150 2.39 1.70 0.195
2.23 1.84
or hydrophilic region; RT, reverse transcriptase.
d/or functional domains: the N terminal region (amino acid 1 to 99), the major
no acid 170 to 226). The MHR includes five subregions: HBsAg subregion 1
ion 3 (amino acid 124 to 137), HBsAg subregion 4 (amino acid 138 to 147) and
erminant (amino acid 124 to 147) spans HBsAg subregions 3 and 4.
Table 4
Amino acid variability in the major hydrophilic region of HBs antigen and reverse transcriptase from patients with concurrent HBsAg and anti-HBs antibodies in serum
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1HBV genotype reference sequences are those from the NCBI HBV genotyping reference panel (http://www.ncbi.nih.gov/projects/genotyping/view.cgi?db=2): genotype A reference sequences: X51970, X02763,
AF090842; genotype B reference sequences: D00329, AF100309, AB033554; genotype D reference sequences: X85254, M32138, X65259; genotype E reference sequences: X75657, AB032431; both amino
acids are noted when two different amino acids are harboured at the same position by reference sequences of the same genotype.
2Proportion of mutated sequences at a given position was calculated as follows: proportion of sequences that do not harbour residue(s) found in HBV reference sequences of the same genotype.
For both HBsAg and reverse transcriptase genes, amino acids harboured by HBV genotypes A, B, D and E from the NCBI HBV genotyping reference panel are shown on the left side. For HBV reference
sequences: only positions with amino acid substitutions in HBsAg and/or reverse transcriptase as compared to HBV reference sequences of genotype A are shown; a dash means the absence of amino acid substitution.
For HBV sequences from patients: only positions with amino acid substitutions in HBsAg and/or reverse transcriptase as compared to HBV reference sequences of corresponding genotype A, B, D or E are
shown; a dash means the absence of amino acid substitution. First codons of HBV sequences from patient Mar-07, Mar-06 and Mar-08, and last codons of HBV sequence from patient Mar-07 were not obtained;
this is indicated by an empty space.
Positions where the proportion of sequences harbouring mutations was significantly higher from HBsAg+/anti-HBsAb+ patients than from controls are marked with an asterisk (pb0.05; see also Figs. 1 and 2); when
wild-type and mutated amino acid(s) are concomitantly found at a given position in bulk sequence, all these amino acids are indicated; indeed, our direct sequencing method allows the detection of mixed sequences
from different HBV quasi-species. Amino acid substitutions found in HBV sequences from HBsAg+/anti-HBsAb+ patients and not from control patients are in a grey font and framed, except for HBV sequences of
genotype B since no sequences of this genotype were found from controls.
35
P.
C
olson
et
al.
/
Virology
367
(2007)
30–40
Fig. 1. Amino acid variability within HBsAg of HBV sequences from HBsAg-positive patients with (dark grey rods) or without (white rods) concomitant anti-HBs in
serum. Amino acid variability was considered the percentage of sequences that harboured at a given position another amino acid than the one found in HBV reference
sequences of the same genotype (found in the genotyping reference set of HBV sequences available on the NCBI Web site; http://www.ncbi.nih.gov/projects/
genotyping/view.cgi?db=2). Positions where the proportion of sequences harbouring mutations was significantly higher from patients with concurrent HBsAg and
anti-HBs antibodies than from controls are marked with an asterisk (see also Table 4).
36 P. Colson et al. / Virology 367 (2007) 30–40that four of these fivemutated positions stand in a “finger” region
of RT overlapping the “a” determinant of the HBsAg MHR.
Substitutions sP120T and sG145R, corresponding to
rtT128N and rtR/W153Q, were found in HBV from one and
three HBsAg+/anti-HBsAb+ patients, respectively. These
mutations are known to restore HBV replication of lamivu-
dine-resistant strains (Torresi et al., 2002a). Of note, one patient
with HBV strains harbouring aa rt153Q was thereafter
efficiently treated with LAM without evidence for viral
resistance after 2 years of monotherapy.Fig. 2. Amino acid variability within RT of HBV sequences from HBsAg-positive
serum. Amino acid variability was considered the percentage of sequences that harbo
sequences of the same genotype (found in the genotyping reference set of HBV
genotyping/view.cgi?db=2). Positions where the proportion of sequences harbouring
anti-HBs antibodies than from controls are marked with an asterisk (see also TableDiscussion
The present study describes the epidemiological, clinical and
virological features of HBsAg+/anti-HBsAb+ patients who
have been tested in Marseilles public hospitals over an 18-
month period.
Prevalence of anti-HBs co-existence was 3.1% in our
population of HBsAg-positive patients. Although unrare, this
is lower than previously reported (up to 36% of HBsAg-positive
patients) (Foutch et al., 1983; Hayashi et al., 1990; Heijtink etpatients with (dark grey rods) or without (white rods) concomitant anti-HBs in
ured at a given position another amino acid that the one found in HBV reference
sequences available on the NCBI Web site, http://www.ncbi.nih.gov/projects/
mutations was significantly higher from patients with concurrent HBsAg and
4).
37P. Colson et al. / Virology 367 (2007) 30–40al., 1982; Lada et al., 2006; Shiels et al., 1987; Tsang et al.,
1986; Wang et al., 1996; Wang et al., 1999; Yamamoto et al.,
1994). The lower prevalence of HBsAg+/anti-HBsAb+ indivi-
duals in our study might be explained by differences between
the characteristics of studied populations, but also by
differences between diagnosis criteria. Thus, in some previous
studies, anti-HBs titers b10 IU/ml were considered positive: if
threshold for anti-HBsAb-positivity was, as in our study, an
anti-HBs titer N10 mIU/ml, which is commonly considered
protective, the prevalence of HBsAg+/anti-HBsAb+ individuals
would not have exceeded 10%.
The concurrent detection of HBsAg and anti-HBsAb may
have important implications on diagnosis. Firstly, this warrants
carrying out systematically both HBsAg and anti-HBsAb assays
in association with the detection of anti-HBc antibodies within
the routine HBV serological diagnosis panel. Indeed, in
individuals with circulating HBsAg and anti-HBsAb in serum,
it would lead to diagnose past HBV infection instead of current
chronic HBV infection. Secondly, decreased recognition of
mutated HBsAg by anti-HBV antibodies used in serological
assays may lead to false negativity of HBsAg detection in these
patients. Thus, in one of our patients (Mar-11), HBsAg was not
detected by our alternative assay (Table 1). The use of this latter
test would have led to diagnosis of past HBV infection instead of
chronicHBVinfection. Of note, HBV from this patient harboured
mutations located at positions previously involved in false-
negative HBsAg results with various assays (P120L, P142L,
D144E and G145R) (Ly et al., 2006). In addition, in two other
patients (Mar-5 and Mar-10), important quantitative differences
were noted for HBsAg between our two diagnosis assays.
Altogether, data of the present study emphasize the need to detect
HBV DNA by using PCR assays when HBsAg and anti-HBsAb
are concurrently detected, or in case of discordance between
clinical and virological patterns with unexplained chronic active
hepatitis and HBsAg negativity in presence of anti-HBsAb.
The clinical significance of the co-existence of HBsAg and
protective levels of anti-HBsAb is not well known since clinical
data are lacking in most studies. Previous studies have suggested
that this profile could be associated with active chronic hepatitis
(Heijtink et al., 1982; Shiels et al., 1987). However, as previously
underlined, they included patients with low anti-HBsAb titers
(b10 mIU/ml), and no clear conclusion could therefore be
drawn. In our study, nearly 40% (five of 13) of HBsAg+/anti-
HBsAb+ patients presented active chronic hepatitis with
advanced fibrosis (Table 1). Furthermore, both the frequency
of HBV DNA detection in serum and HBV DNA levels were
significantly higher in our HBsAg+/anti-HBsAb+ patients than
in control patients without anti-HBsAb (Table 2). These data
suggest that this serological profile might be frequently
associated with HBV replication and active chronic hepatitis,
despite the presence of anti-HBsAb at a protective level.
The advanced liver fibrosis observed in HBsAg+/anti-
HBsAb+ patients in the present study might be related to a long
history of HBV chronic infection since their median age was
higher as compared to controls (59 vs. 43 years, respectively).
It must be also highlighted that a context of immune
suppression was found in a majority (69%) of our HBsAg+/anti-HBsAb+ patients (Table 1). This could have contributed to the
high proportion of advanced liver diseases observed in these
patients, as previously described in HIV-1-infected individuals
(Konopnicki et al., 2005). Moreover, this may suggest that in
HBsAg+/anti-HBsAb+ individuals, inadequate HBV-specific
immune pressure favored the emergence of immune escape
HBV mutants, not fully neutralized by anti-HBsAb in serum.
Thus, an important finding in our study is that, as previously
reported by Lada et al. (2006), HBV fromHBsAg+/anti-HBsAb+
patients exhibited significantly higher HBsAg aa variability
than controls (Tables 3 and 4; Fig. 1). These mutations were
mostly located within the “a” determinant of the HBsAg MHR,
which is considered to be the major target of protective anti-
HBsAb (Carman, 1997; Weber, 2005). The impact on HBsAg
antigenicity of these mutations, either alone or in combination,
still needs to be further characterized for most of them.
However, it is striking that some substitutions found in our
patients at positions 120, 126, 144 and 145, and associated with
alteration of HBsAg antigenicity, were previously reported in
HBsAg+/anti-HBsAb+ patients (Carman, 1997; Kfoury Baz et
al., 2001; Kohno et al., 1996; Lada et al., 2006; Lee et al., 2001;
Lu and Lorentz, 2003; Wang et al., 1999; Weber, 2005;
Weinberger et al., 2000; Yamamoto et al., 1994). Hence, the
selection as major quasi-species of such HBsAg HBV variants
harbouring various aa substitutions in and around the “a”
determinant may reflect their potential to escape to neutraliza-
tion by the immune system, including to anti-HBsAb.
These data raise the important concern whether or not
individuals harbouring such HBsAg mutated HBV strains could
represent a reservoir for dissemination of HBV, even to
vaccinated individuals (Carman, 1997; Torresi et al., 2002b;
Weber, 2005; Zuckerman and Zuckerman, 2003). Despite
remaining unclear, this warrants particular attention in our
patients since most of them are immunosuppressed and have
been receiving health care in clinical units where they were in
contact with individuals presenting similar immunological status
(Pawlotsky, 2005).
In the present study, we also observed a significantly higher aa
variability within RT of HBV from HBsAg+/anti-HBsAb+
patients than from controls. We specifically observed a
significantly higher aa variability in the RT region overlapping
the C terminal region of HBsAg. This region encompasses the B,
C and D domains of HBV RT where resistance mutations to
antiviral drugs occur. An impact of HBsAg mutations on HBV
RT functionality and drug susceptibility could be a critical issue
since, as previously discussed, most of HBsAg+/anti-HBsAb+
patients might be candidate for initiation of an antiviral therapy.
Although the virological and clinical implications of our findings
remain unclear, some of the HBV RT mutations observed from
our patients before any antiviral therapy have been already
associated with specific clinical outcomes following treatment
initiation. Amino acids rt128N and/or rt153Q, corresponding to
s120Tand s145R and observed in four patients in our study, were
previously found to partially restore the in vitro replication of
LAM-resistant HBV strains (Torresi et al., 2002a). In addition,
we observed in HBV from one patient the substitution rtV207M
that corresponds to sM198I and was previously found to be
38 P. Colson et al. / Virology 367 (2007) 30–40selected during lamivudine treatment (Mar-6; Table 4) (Torresi et
al., 2002b). Amino acids s207R and rt215S were also observed
in one patient (Mar-13), and interestingly they were described in
ADV-resistant strains in a recent study (Yim et al., 2006).
Therefore, our data deserve careful follow-up of these patients
once antiviral drugs are introduced.
In summary, this study has shown a low but not negligible
prevalence of anti-HBsAb co-existence in HBsAg-positive
patients. This serological pattern might be associated with active
chronic HBVinfection and immunosuppression.We observed an
increased aa variability of HBV strains within both HBsAg and
RT involving functionally important regions of those proteins.
Further studies are needed to determine whether these combina-
tion envelope and polymerase gene HBV mutants might
disseminate, including to vaccinated individuals, and might
limit the long-term efficacy of nucleos(t)ide analogs therapies.
Materials and methods
Patients
We undertook a retrospective screening of concurrent
HBsAg/anti-HBsAb-positivity in all patients whose HBV sero-
logical status was tested in Marseilles public hospitals from
November 2003 to April 2005 (18 months). Patients who
received passive immunization, including anti-HBs immuno-
globulines following liver transplantation, were excluded from
the study. For comparative analysis of virological patterns
including HBsAg and RT regions, a control group consisting in
123 individuals with newly diagnosed HBsAg positivity and
without anti-HBsAb over a 12-month concomitant period (May
2003–April 2004) was used; HBV sequences have been
obtained from 51 of them.
Serological assays
HBV serological markers were performed by using the
Axsym Abbott enzyme-immunoassays (HBsAg v2.0, Abbott,
Diagnostics Division, Wiesbaden, Germany). HBsAg positivity
was confirmed by a neutralization assay (Abbott, Diagnostics
Division). Concurrent HBsAg/anti-HBsAb-positivity was
defined by positive reactivity for HBsAg and anti-HBsAb titers
N10 mIU/ml. An additional testing of HBsAg and anti-HBsAb
was performed in all cases by using Vidas BioMérieux assays
(BioMérieux, Marcy-l'Etoile, France).
HBV DNA quantification in serum
HBV DNA was quantified in serum using the Cobas
Amplicor HBV Monitor kit (Roche Diagnostics, Meylan,
France) with a lower detection threshold of 200 copies/ml.
HBV genotyping
For HBV DNA sequencing, HBV DNA was extracted from
serum then amplified and sequenced using in-house protocols,
as follows.Nucleic acid extraction and purification
Whole blood was collected in dry tubes with gel separator.
Serum was aliquoted after a centrifugation step and stored at
−80 °C until it was processed. HBV DNA was extracted from
1000 μl of serum after an ultracentrifugation step at 23,000×g
for 1 h using the QIAamp DNA minikit (Qiagen, Courtaboeuf,
France), with a digestion step extended to 90 min; elution was
performed using 100 μl of elution buffer. Prepared DNA were
directly analyzed or stored at −80 °C.
Nucleic acid PCR amplification and DNA sequencing
Amplification and direct sequencing for the full-length
HBsAg coding-region (aa 1–226) and the entire RT gene were
performed using in-house protocols as follows. Ten microliters
of extracted HBV DNAwas amplified using Hot StarTaq DNA
polymerase (Qiagen) using 10 pmol of the outer primers
(MrsBRaFwd: 5′gtggctccagttcaggaac, 64 nt; MrsBRbRev: 5′
gagcaaaacaagcggctagg, 1282; primer location was defined in
reference to HBV sequence GenBank accession no. X65259) to
obtain a PCR product of 1237 bp. This was carried out in a 50-μl
reaction mixture under the conditions recommended by the
manufacturer, with a polymerase activation-initial denaturation
step at 95 °C for 15 min, followed by 40 amplification cycles (for
30 s at 95 °C, 120 s at 56 °C, 2 min at 72 °C) and then an
elongation step at 72 °C for 10 min. Semi-nested-PCR was
performed when no PCR-amplified DNA fragments could be
detected after single round PCR (corresponding to serum sample
containing low amounts of HBV DNA, below nearly 104 copies/
ml), using 3 μl of the first round amplification product with
50 pmol of inner primers (MrsBRcFwd: 5′agtaaaccctgctccgaatatt,
83; MrsBRbRev) in a final volume of 50 μl to obtain DNA
fragments of 1218 bp. PCR conditions were as for first round of
PCR. The PCR-amplified DNA fragments were purified using
NucleoFast 96 (Macherey-Nagel, Düren, Germany) according to
manufacturer instructions, then used as the DNA template for
nucleotide sequencing of the HBsAg-RT coding region with five
primers (MrsBRcFwd; MrsBRbRev; MrsBSq5Fwd: 5′ctcagtttac-
tagtgccatt, 672; MrsBSq6Rev: 5′cccccaataccacatcatcc, 742;
MrsBPol5Fwd: 5′ctcgtgttacaggcggggtt, 192). Cycle sequencing
of both strands was performed on the GeneAmp PCR system
9600 instrument (Applied-Biosystems, Branchburg, NJ, USA)
with the Big Dye Terminator Cycle sequencing kit v1.1 (Applied-
Biosystems). The extension products were purified with Sepha-
dex G-50 Superfine on MAHVN 45–50 plates (Millipore,
Molsheim, France) then sequenced on ABI Prism 3130 genetic
analyzer (Applied-Biosystems). Nucleotide sequences were
aligned using Seqscape software v2.5 (Applied-Biosystems)
then compared with a set of sequences available in GenBank
for genotype determination using the MEGA software (Kumar
et al., 1994).
Analysis of amino acid substitutions within HBsAg and reverse
transcriptase
The nucleotide HBsAg/RT sequences obtained were
translated into amino acid sequences, aligned and compared
with HBV sequences of the same genotype found in the
39P. Colson et al. / Virology 367 (2007) 30–40genotyping reference set available on the NCBI Web site
(http://www.ncbi.nih.gov/projects/genotyping/view.cgi?db=2).
Amino acid variability was defined as the proportion, at each
position, of sequences that did not harbour the aa found in
HBV reference sequences of the same genotype. For analysis,
HBsAg was divided into subregions corresponding to
structural and/or functional domains: the N terminal region
(amino acid 1 to 99), the major hydrophilic region (MHR;
amino acid 100 to 169) and the C terminal region (amino acid
170 to 226). The MHR includes five subregions: HBsAg
subregion 1 (amino acid 100 to 120), HBsAg subregion 2
(amino acid 121 to 123), HBsAg subregion 3 (amino acid 124
to 137), HBsAg subregion 4 (amino acid 138 to 147) and
HBsAg subregion 5 (amino acid 148 to 169). The “a”
determinant (amino acid 124 to 147) spans HBsAg subregions
3 and 4 (Cooreman et al., 2001).
Statistical analysis
Results were collected and analyzed using Microsoft Access
software. Statistical analysis was performed using the SPSS
software v10.1.3.
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